Randomized Embedded Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • End date
    Dec 18, 2023
  • participants needed
  • sponsor
    MJM Bonten
Updated on 18 October 2020
Genevieve O' Neill
Primary Contact
Royal North Shore Hospital (5.0 mi away) Contact
+107 other location


REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.


Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.

Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.

This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:

  • Evaluate multiple treatment strategies, at the same time, in the same patient.
  • Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
  • Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
  • New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
  • Interactions between interventions in different domains can be evaluated

It is reasonable to presume that any pandemic respiratory infection of major significance to public health will manifest as life-threatening respiratory infection including Severe Acute Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous pandemics and more localized outbreaks of respiratory emerging infections have resulted in severe CAP and ICU admission.

Previous pandemics and outbreaks of emerging infectious diseases have outlined the urgent need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best treatment. However, there are substantial challenges associated with being able to organize such trials when the time of onset of a pandemic and its exact nature are unpredictable. As an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing treatments as well as novel approaches.

Treatment Clopidogrel, Lopinavir/Ritonavir, prasugrel, Aspirin, Tocilizumab, Anakinra, Vitamin C, Amoxicillin-clavulanate, Apremilast, Hydrocortisone, Simvastatin, ceftriaxone, hydroxychloroquine, Ticagrelor, ECCO2R, Ceftaroline, Amoxicillin Clavulanate, Piperacillin-tazobactam, Antibiotic A, Antibiotic B, Minimal distension, Maximal recruitment, Piperacillin tazobactam, Sarilumab, Moxifloxacin or Levofloxacin, Macrolide administered for 3 days, Macrolide administered for up to 14 days, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Macrolide administered for 3-5 days, Five-days oseltamivir, Ten-days oseltamivir, Hydroxychloroquine + lopinavir/ritonavir, Convalescent plasma, Interferon-β1a, Fixed-duration higher dose Hydrocortisone, Therapeutic Anticoagulation, Protocolised mechanical ventilation strategy, Eritoran
Clinical Study IdentifierNCT02735707
SponsorMJM Bonten
Last Modified on18 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Covid-19 or Community-acquired Pneumonia, Influenza, COVID-19 or Community Acquired Pneumonia?
Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission
symptoms or signs or both that are consistent with lower respiratory tract infection AND
Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
Up to 48 hours after ICU admission, receiving organ support with one or more of
Non-invasive or Invasive ventilatory support
Receiving infusion of vasopressor or inotropes or both

Exclusion Criteria

Healthcare-associated pneumonia
Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
Resident of a nursing home or long term care facility
Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
Previous participation in this REMAP within the last 90 days
Adult patients ( 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection
Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
Patient is expected to be discharged from hospital today or tomorrow
More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection
Previous participation in this REMAP within the last 90 days
Each domain may have additional eligibility criteria. Refer to the study
website for more information ([www.remapcap.org](http://www.remapcap.org/))
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet